Pharmacokienetic studies on Docetaxel in breast cancer Patients - Omran, Mervat
36,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
18 °P sammeln
  • Broschiertes Buch

Worldwide, breast cancer is the leading type of cancer in women. Among Egyptian women breast cancer showed the highest frequencies among all cancers. Docetaxel (DCX) is one of the chemotherapy medication used to treat breast cancer which mainly metabolized in the liver by cytochrome3A4. The present study was conducted to study pharmacokinetic and pharmacodynamic properties of DCX in Egyptian breast cancer patients and the interpatient variability of cytochrome3A4 activity, as estimated using urinary metabolites of exogenous cortisol. The practical work was take place in NCI, Cairo University, Egypt.…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Worldwide, breast cancer is the leading type of cancer in women. Among Egyptian women breast cancer showed the highest frequencies among all cancers. Docetaxel (DCX) is one of the chemotherapy medication used to treat breast cancer which mainly metabolized in the liver by cytochrome3A4. The present study was conducted to study pharmacokinetic and pharmacodynamic properties of DCX in Egyptian breast cancer patients and the interpatient variability of cytochrome3A4 activity, as estimated using urinary metabolites of exogenous cortisol. The practical work was take place in NCI, Cairo University, Egypt.
Autorenporträt
Mervat Omran is a Pharmacology lecturer in National Cancer Institute (NCI), Cairo University. She got her bachelor and Master degree from faculty of Pharmacy, Ain Shams University, and PhD from NCI. Her researches focused in pharmacokinetics of different chemotherapy drugs especially in breast and hematological cancer.